Rapamycin remains the most validated longevity drug, but it isn't accessible to everyone. Here are the five best alternatives in 2026 — what they reproduce, what they don't, and how to use each.
Rapamycin is the gold standard for mTOR-targeted longevity intervention. The Interventions Testing Program has reproduced its lifespan benefit across more than a dozen mouse cohorts, and human pulse-dosing protocols have been used safely for years in private practice. But not everyone can access it. Some people lack a prescribing physician. Some have contraindications. Some live in jurisdictions where off-label rapamycin prescribing is uncommon.
This guide ranks the five best commercially available compounds that target overlapping mechanisms in 2026 — what each one does, what it doesn't, and how to think about it as a partial substitute.
Rapamycin's longevity-relevant effect is intermittent inhibition of the mTORC1 (mechanistic target of rapamycin complex 1) signaling pathway. mTORC1 integrates nutrient and growth signals; persistent activation drives anabolic processes, suppresses autophagy, and is implicated in age-related decline. Pulsing mTORC1 inhibition shifts cellular physiology toward maintenance, repair, and autophagy — the same broad direction that caloric restriction pushes.
A "rapamycin alternative" is a compound that produces some directional shift along that axis. None match rapamycin's potency, specificity, or evidence base. But several do meaningful work.
Metformin activates AMPK, the energy sensor that opposes mTOR. The downstream effects on autophagy, mitochondrial biogenesis, and cellular maintenance partially overlap with rapamycin's effects. The TAME trial (now delayed but still active) is testing whether metformin slows multiple age-related diseases in non-diabetic adults.